Atrogi announces first patient treated with Adrenoceptor agonist
first patient treated witH ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Atrogi announced today that the first patient has been enrolled in a Phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel ß2 adrenoceptor agonist with a unique mechanism of action for the …
Atrogi announces first patient treated with Adrenoceptor agonist Read More »